PerkinElmer SARS-COv-2 Serological Test Platforms
Supports rapid decisions ✓ Support population screening to monitoring the Covid-19 spread ✓ Flexible solution to meet different throughput requirements more
PerkinElmer complete workflow solution for SARS-CoV-2 PCR detection enables labs to maintain sample integrity and avoid cross-contamination by providing validated, modular and scalable, automated workflow solutions. Our SARS-CoV-2 Real-time RT-PCR assay provides reliable and high-quality results for the clinical detection of COVID-19 in human oropharyngeal and nasopharyngeal swab, BAL, sputum, plasma or serum samples. Our chemagen™ technology prevents degradation and enzymatic inhibitors while providing high recovery rate of nucleic acid extraction.
Our liquid handling systems allow a reduction in the risk of exposing laboratory employees to pathogens while increasing the robustness of the workflow. Additionally, our newest PKamp™ Respiratory SARS-CoV-2 RT-PCR Panel assay is a real-time RT-PCR multiplexed test intended for the simultaneous qualitative detection and differentiation of SARS-CoV-2, influenza A, influenza B and respiratory syncytial virus (RSV) that allows for ongoing flu and RSV surveillance while also testing for SARS-CoV-2.
PerkinElmer SARS-COv-2 Serological Test Platforms
Supports rapid decisions ✓ Support population screening to monitoring the Covid-19 spread ✓ Flexible solution to meet different throughput requirements more
DUAL SOURCE - true inline ESI/APCI multiplexing flexibility ✓ STAYCLEAN SOURCE and HSID INTERFACE - laminar flow for longterm reproducable results ✓ SIMPLICITY 3Q Software - intuitive data method setup and clearly arranged result reporting more
Superior interference removal ✓ Outstanding background equivalent concentrations and detection limits ✓ Exceptional stability more
PerkinElmer Completes Acquisition of Oxford Immunotec
PerkinElmer, Inc. announced that the Company has completed its previously announced acquisition of Oxford Immunotec Global PLC (Oxford Immunotec). PerkinElmer originally announced its intent to acquire Oxford Immunotec on January 7, 2021. “Oxford Immunotec’s global role in fighting tubercul ... more
FDA Provides Emergency Use Authorization to PerkinElmer for COVID-19 Testing
PerkinElmer, Inc. announced that the U.S. Food and Drug Administration (FDA) has provided Emergency Use Authorization (EUA) for the Company’s New Coronavirus RT-PCR test. Clinical laboratories certified under Clinical Laboratory Improvement Amendments (CLIA) can immediately begin using this ... more
PerkinElmer Announces Leadership Succession Plan
PerkinElmer, Inc. announced that after a career of more than 20 years at the Company, including the last 12 years as chief executive officer, Robert F. Friel, has decided to retire as chairman and CEO and member of the board of directors as of the end of the Company’s fiscal year on Decembe ... more